BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Active Biotech AB (BTPC) Interim Report January - June 2012


8/10/2012 9:49:51 AM

LUND, SWEDEN--(Marketwire - August 10, 2012) -

* Laquinimod - application submitted for regulatory approval in the EU resulting in milestone payment of USD 5 M during third quarter 2012 - a Phase III study will be initiated in the US

* TASQ - milestone payment of EUR 10 M received from Ipsen in connection with meeting patient enrolment target for Phase III study - overall survival data from Phase II study presented

* ANYARA - Phase III trial continuing according to plan

* 57-57 - a clinical trial in systemic sclerosis/scleroderma in progress

* ISI - project proceeding as planned

* The organization has been adapted to the company's new direction

* Net sales: SEK 96.6 M (228.8)

* Operating loss: SEK 120.6 M (profit: 70.6)

* Loss after tax: SEK 123.5 M (profit: 77.7)

* Loss per share for the period: SEK 1.79 (earnings: 1.14)


This report is also available at www.activebiotech.com
Fax: +46 (0)46 19 11 00


Active Biotech AB Interim report Jan - June 2012: http://hugin.info/1002/R/1633117/523993.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1633117]


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->